Preliminary security investigation and short-time follow-up of intraoperative intraperitoneal chemotherapy with lobaplatin for advanced colorectal cancer

Abstract

Abstract Objective The aim of this study was to conduct a security assessment of intraoperative intraperitoneal chemotherapy using lobaplatin for advanced colorectal cancer. Methods From February 2015 to February 2016, 143 patients with colorectal cancer who underwent surgery in our department were selected prospectively. All patients were randomly screened and enrolled into the intraperitoneal chemotherapy (IPC) (74 cases) and control (69 cases) groups, depending on the distribution of cases in the random table. In the trial group, patients were administered 40 mg lobaplatin by intraperitoneal implantation intraoperatively, together with intravenous chemotherapy post-operatively using a typical FOLFOX strategy with oxaliplatin, fluorouracil, and leucovorin. In the control group, only FOLFOX was administered. Bowel function recovery time, adverse reactions and complications, and pre-and post-chemotherapy laboratory examinations were compared. In addition, a 5-year-long follow-up was performed. Results Recovery times of bowel function were 73.5 ± 9.7 h and 74.8 ± 10.3 h respectively, and the difference was not significant (P > 0.05). Wound fat liquefaction was observed in five cases in both groups (6.8% vs. 7.2%, P > 0.05). The outcomes of nausea and vomiting (57 cases, 77.0% vs. 50 cases, 72.5%), constipation (43 cases, 58.1% vs. 36 cases, 52.2%), and diarrhea (5 cases, 6.8% vs. 5 cases, 7.2%) were not statistically significant (all P > 0.05). Indices of white blood cell count, blood platelet count, and hepatorenal function were not significantly different (all P>0.05) neither post-operatively nor post-chemotherapy. The 5-year survival rate was not significantly different between the groups (58.1% vs. 56.5%, P > 0.05). Conclusion Intraoperative chemotherapy with lobaplatin for advanced colorectal cancer is safe and tolerable.